TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32947587

Group type: EXPERIMENTAL
Intervention: Running subcuticular closure
Number of subjects: 75

Group type: COMPARATOR
Intervention: Simple, horizontal mattress, vertical mattress, and AD techniques
Number of subjects: 75
Study: 35320813

Group type: EXPERIMENTAL
Intervention: Tongue-pressure resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional swallowing rehabilitation treatment
Number of subjects: 0
Study: 35325449

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve + Rossetti Fundoplication (SG + RF)
Number of subjects: 138
Study: 32224489

Group type: EXPERIMENTAL
Intervention: Affect-focused internet-based psychodynamic therapy (IPDT) for 8 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Supportive control for 8 weeks
Number of subjects: 76
Study: 33278179

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 34582037

Group type: COMPARATOR
Intervention: Continuous infusion of ropivacaine 0.2% at 6 ml/h
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Programmed, intermittent boluses of ropivacaine 0.2% at 10 ml every 8th hour
Number of subjects: 81

Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Programmed, intermittent boluses
Number of subjects: 81
Study: 34174225

Group type: EXPERIMENTAL
Intervention: Exoskeleton-Assisted Anthropomorphic Movement Training (EAMT) therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional upper limb therapy
Number of subjects: 20
Study: 36170964

Group type: EXPERIMENTAL
Intervention: 30 g milk protein (MILK)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 30 g plant-derived protein blend (PLANT-BLEND) combining 15 g wheat, 7.5 g corn, and 7.5 g pea protein
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both MILK and PLANT-BLEND
Number of subjects: 24
Study: 33471564

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) 2.0 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg
Number of subjects: 49
Study: 32392169

Group type: EXPERIMENTAL
Intervention: Biplane imaging
Number of subjects: 430
Study: 34231450

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Attention- and time-matched control
Number of subjects: 163
Study: 34420947

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT)
Number of subjects: 133
Study: 32557601

Group type: EXPERIMENTAL
Intervention: Ribociclib 400 mg single-dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple 400 mg ribociclib doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple 600 mg ribociclib doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir with ribociclib 600 mg multiple doses
Number of subjects: 0
Study: 35986262

Group type: EXPERIMENTAL
Intervention: SMS-based education
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Group-based education
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Comparison between SMS and group-based education
Number of subjects: 168
Study: 33783964

Group type: EXPERIMENTAL
Intervention: LY2963016 insulin glargine (LY IGlar)
Number of subjects: 536

Group type: COMPARATOR
Intervention: Insulin glargine (Lantus; IGlar)
Number of subjects: 536
Study: 32083368

Group type: EXPERIMENTAL
Intervention: Dronedarone (cardioversion)
Number of subjects: 1237

Group type: EXPERIMENTAL
Intervention: Dronedarone (non-cardioversion)
Number of subjects: 1237

Group type: COMPARATOR
Intervention: Dronedarone
Number of subjects: 1237
Study: 36441735

Group type: EXPERIMENTAL
Intervention: Health Belief Model‐Based Intervention (HEBI) module
Number of subjects: 284

Group type: COMPARATOR
Intervention: Health talk on non‐communicable disease (Control)
Number of subjects: 284
Study: 35751029

Group type: EXPERIMENTAL
Intervention: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in PD patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in NPD patients
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Probit analysis of remifentanil in PD patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Probit analysis of remifentanil in NPD patients
Number of subjects: 47
Study: 32620620

Group type: EXPERIMENTAL
Intervention: Second primary endometrial cancer (SPEC) patients with greater than a 10-year interval from prior malignancy
Number of subjects: 326

Group type: COMPARATOR
Intervention: First primary endometrial cancer (FPEC) patients
Number of subjects: 326
Study: 35312741

Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34120613

Group type: EXPERIMENTAL
Intervention: Major depression among female sex workers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Life stress
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Living with HIV
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Verbal abuse
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Provision of sexual services from clients' homes
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Use of a non-barrier modern family planning method
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Daily intake of alcohol
Number of subjects: 300
Study: 33586144

Group type: EXPERIMENTAL
Intervention: Right unilateral (RUL) ECT
Number of subjects: 138

Group type: COMPARATOR
Intervention: Bitemporal (BT) ECT
Number of subjects: 138
Study: 35587720

Group type: EXPERIMENTAL
Intervention: INDDEX24
Number of subjects: 234

Group type: COMPARATOR
Intervention: PAPI
Number of subjects: 234
Study: 34411872

Group type: EXPERIMENTAL
Intervention: Rational Emotive Behavior Therapy (REBT), 8-week group-based counseling sessions
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 42
Study: 34864864

Group type: EXPERIMENTAL
Intervention: Throat packing
Number of subjects: 101

Group type: COMPARATOR
Intervention: No throat packing
Number of subjects: 101
Study: 33532993

Group type: EXPERIMENTAL
Intervention: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at 30 min interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at more than 30 min interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PIEB regimen
Number of subjects: 20
Study: 35451604

Group type: EXPERIMENTAL
Intervention: READ training
Number of subjects: 570
Study: 35351058

Group type: EXPERIMENTAL
Intervention: Personalized radiotherapy (RT) using PSMA-PET
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patient empowerment project for training of bladder preparation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pilot trial investigating safety of PSMA-PET for focal dose escalation RT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: In-silico RT planning studies
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Urethral sparing in focal dose escalation
Number of subjects: 50
Study: 32106189

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality curriculum (30-minute session using OculusRift headset)
Number of subjects: 168
Study: 35089999

Group type: EXPERIMENTAL
Intervention: Green tea containing 550 mg mulberry leaf extract (MLE), 3 times a day for 4 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control beverage (green tea not containing MLE), 3 times a day for 4 weeks
Number of subjects: 48
Study: 32854125

Group type: EXPERIMENTAL
Intervention: Immediate operative therapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Preoperative risk factors (leukocytosis, increased CRP-level, bi- or trimalleolar fracture type)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus and elevated ASA score
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Prognostic models for prolonged LOS and postoperative complications
Number of subjects: 154
Study: 36190440

Group type: EXPERIMENTAL
Intervention: Pimavanserin 20 mg (adjusted to 34 or 10 mg between weeks 2-8)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34498304

Group type: EXPERIMENTAL
Intervention: MaiStep delivered by psychologists or teachers (IG-T)
Number of subjects: 1654

Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 1654
Study: 35098659

Group type: EXPERIMENTAL
Intervention: Support and problem solving
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural case management
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids or low-dose antipsychotic medication (fast-fail option)
Number of subjects: 342
Study: 33019891

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa) or >30 ng/mL (group IIb)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No preoperative vitamin D supplementation (group I)
Number of subjects: 102
Study: 32898192

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg tablet formulation (F-15)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Marketed brand (ACEMED)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 12
Study: 34723864

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mg/kg ideal body weight)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 34
Study: 32269278

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 57
Study: 34674610

Group type: EXPERIMENTAL
Intervention: Standardized extract of Calendula officinalis L. (SEC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mineral oil (Control Group)
Number of subjects: 40
Study: 33781304

Group type: EXPERIMENTAL
Intervention: Face mask use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Underpowered trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No trials
Number of subjects: 0
Study: 32187097

Group type: EXPERIMENTAL
Intervention: Local multimodal drug injection (ropivacaine 10 mL, morphine 5 mL, ceftezole 5 mL, normal saline 5 mL)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Local multimodal drug injection
Number of subjects: 101
Study: 35206123

Group type: EXPERIMENTAL
Intervention: Abriendo Caminos intervention
Number of subjects: 365
Study: 33935137

Group type: EXPERIMENTAL
Intervention: New drug comorbidity index
Number of subjects: 598664

Group type: COMPARATOR
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 598664
Study: 35976205

Group type: EXPERIMENTAL
Intervention: Omaha System-based continuing care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 100
Study: 32036960

Group type: EXPERIMENTAL
Intervention: Higher dietary Met level (45% of Lys content)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lowest Arg level (90% of Lys content)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Highest Arg level (110% of Lys content)
Number of subjects: 108
Study: 33962902

Group type: EXPERIMENTAL
Intervention: Daily delivery of a single whole egg per day added to local standard nutrition care for 6 months
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Local standard nutrition care package alone
Number of subjects: 1200
Study: 34657452

Group type: EXPERIMENTAL
Intervention: Lay patient navigator (LPN) navigation for 6 months, including discussions on survivorship care planning and accompanying patients to primary care appointments.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 40
Study: 33015924

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 503

Group type: COMPARATOR
Intervention: Polypharmacy
Number of subjects: 503
Study: 33165153

Group type: EXPERIMENTAL
Intervention: Multimodal neuroimaging-based customized TMS treatment
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Multimodal neuroimaging approaches
Number of subjects: 97
Study: 36457068

Group type: EXPERIMENTAL
Intervention: Esketamine 0.2 mg/kg IV before induction of anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ineffective group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Effective group (patients with negative pain response)
Number of subjects: 30
Study: 34186473

Group type: EXPERIMENTAL
Intervention: Combination of medications including opioids and other medications inconsistent with national (NICE) guidance
Number of subjects: 33

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 33
Study: 35151982

Group type: EXPERIMENTAL
Intervention: Action (high‐intensity stimuli) games in VR for 30 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Adventure (low‐intensity stimuli) games in VR for 30 min
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Videogamers
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 80
Study: 35770596

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at 2/20-25 Hz for 30 minutes at points ST36, SP6, LI4, and LR3
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no EA)
Number of subjects: 28
Study: 35690073

Group type: COMPARATOR
Intervention: 3‐weekly carboplatin AUC5 or AUC6 and 3‐weekly paclitaxel 175 mg/m2 (control; group 1)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: 3‐weekly carboplatin AUC5 or AUC6 and weekly paclitaxel 80 mg/m2 (group 2)
Number of subjects: 1566

Group type: EXPERIMENTAL
Intervention: Weekly carboplatin AUC2 and weekly paclitaxel 80 mg/m2 (group 3)
Number of subjects: 1566
Study: 34678909

Group type: EXPERIMENTAL
Intervention: Group rational-emotive behavioral education intervention (REBEI)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 32170964

Group type: EXPERIMENTAL
Intervention: Minocycline (200mg then 100mg b.i.d. for 7 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Placebo (days 0-7) then Minocycline (days 7-14)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Minocycline (days 0-7) then Placebo (days 7-14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Initial cohort (no treatment)
Number of subjects: 28
Study: 35279528

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 34409927

Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination (DRE)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Free/Total PSA
Number of subjects: 270
Study: 32554105

Group type: EXPERIMENTAL
Intervention: Collaborative care program
Number of subjects: 328

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 328
Study: 34480787

Group type: EXPERIMENTAL
Intervention: Fingolimod + tPA
Number of subjects: 75

Group type: COMPARATOR
Intervention: tPA only
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: USPIO injection (5.6 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: USPIO injection (16.8 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: USPIO injection (56 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Visual cortical vessels in ischemic regions
Number of subjects: 75

Group type: COMPARATOR
Intervention: Visual cortical vessels in control regions
Number of subjects: 75
Study: 34812502

Group type: EXPERIMENTAL
Intervention: High-score group (GDF15, AFP, FIB-4 index scoring)
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Medium-score group (GDF15, AFP, FIB-4 index scoring)
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Low-score group (GDF15, AFP, FIB-4 index scoring)
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Patients with FIB-4 index ≤3.25
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Medium-score group (FIB-4 index ≤3.25)
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Low-score group (FIB-4 index ≤3.25)
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: Baseline GDF15 >1350 pg/mL
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: AFP >5 ng/mL
Number of subjects: 1606

Group type: EXPERIMENTAL
Intervention: FIB-4 index >3.25
Number of subjects: 1606
Study: 34904015

Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin Detemir
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (comparison between Glargine and Detemir)
Number of subjects: 40
Study: 32858543

Group type: EXPERIMENTAL
Intervention: Online physical activity promotion program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 32838817

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise for 8 weeks (n = 35)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Light stretching for 8 weeks (n = 31)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 66
Study: 32901733

Group type: EXPERIMENTAL
Intervention: Autologous bone chips (group 1)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Autologous bone chips mixed 1:1 with porcine-derived xenogenic bone (group 2)
Number of subjects: 11
Study: 34800357

Group type: EXPERIMENTAL
Intervention: Temperature-controlled intraductal radiofrequency ablation (ID-RFA) and bilateral plastic stent (PS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bilateral plastic stent (PS)
Number of subjects: 30
Study: 32149764

Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia (group DES)
Number of subjects: 200
Study: 36221414

Group type: EXPERIMENTAL
Intervention: Controlled silicone swelling using KF-96A-10CS oil, applied in 2 to 6 brush-coats.
Number of subjects: 24
Study: 33583479

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 2919

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2919
Study: 32559759

Group type: EXPERIMENTAL
Intervention: Nicotine sated state
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nicotine withdrawal
Number of subjects: 30
Study: 32511015

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy interventions for anxiety
Number of subjects: 167

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Pre-treatment accommodation
Number of subjects: 167
Study: 32013901

Group type: EXPERIMENTAL
Intervention: School garden programme with complementary WASH, health and nutrition interventions (SG+); n=197 children
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group; n=313 children
Number of subjects: 682
Study: 35905577

Group type: EXPERIMENTAL
Intervention: Group CBT for 8 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 106
Study: 33670508

Group type: EXPERIMENTAL
Intervention: Diaphragmatic contraction
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diaphragmatic relaxation
Number of subjects: 16
Study: 33573859

Group type: EXPERIMENTAL
Intervention: LUTS prevalence
Number of subjects: 2745

Group type: EXPERIMENTAL
Intervention: Risk factors for LUTS presence
Number of subjects: 2745
Study: 33765619

Group type: EXPERIMENTAL
Intervention: Autonomy group (n = 17)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Choice-RT task first
Number of subjects: 59

Group type: COMPARATOR
Intervention: No-autonomy group (n = 17)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Simon task first (chosen by 9 of 17 in autonomy group)
Number of subjects: 59
Study: 36008795

Group type: EXPERIMENTAL
Intervention: Myofunctional treatment (MB-M group)
Number of subjects: 224

Group type: COMPARATOR
Intervention: No treatment (MB-N group)
Number of subjects: 224

Group type: COMPARATOR
Intervention: No treatment (NB group)
Number of subjects: 224
Study: 32247194

Group type: EXPERIMENTAL
Intervention: Model incorporating individual symptoms and baseline characteristics
Number of subjects: 997

Group type: COMPARATOR
Intervention: Model including early improvement in overall depression only
Number of subjects: 997
Study: 35295986

Group type: EXPERIMENTAL
Intervention: Liothyronine 0.7 mcg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Levothyroxine 0.86 mcg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 32186696

Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative rehabilitation
Number of subjects: 0
Study: 34898075

Group type: EXPERIMENTAL
Intervention: Linshu Decoction (1 dose bid) combined with levofloxacin (0.1 g bid)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Levofloxacin (0.1 g bid)
Number of subjects: 115
Study: 36195170

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 2485

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 2485

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 2485
Study: 33407619

Group type: EXPERIMENTAL
Intervention: Peg-interferon treatment
Number of subjects: 30
Study: 32483957

Group type: EXPERIMENTAL
Intervention: Tramadol 1mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metamizole 30mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no preemptive analgesia)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Comparison between tramadol and metamizole
Number of subjects: 90
Study: 35610581

Group type: EXPERIMENTAL
Intervention: Anticipatory Care Planning (ACP) intervention delivered by a registered nurse including home-based patient assessment, care planning, and documentation of a support plan.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Anticipatory Care Planning (ACP) intervention
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 65
Study: 32088676

Group type: EXPERIMENTAL
Intervention: AL-TENS
Number of subjects: 30

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 30